Skip to content
10-Q

Quarterly Report

KINNATE BIOPHARMA INC.

0001140361-23-024155

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 46.57M sh
Shares Diluted Q1 2023 · Mar 31, 2023 45.41M sh
Shares Diluted Q1 2023 · Mar 31, 2022 43.88M sh
Capex Q1 2023 · Mar 31, 2023 $9K
Capex Q1 2023 · Mar 31, 2022 $2.02M
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$27.72M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$21.09M
Short Term Investments Q1 2023 · Mar 31, 2023 $127.41M
Short Term Investments Q1 2023 · Dec 31, 2022 $172.21M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $73.57M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $29.26M
Stockholders Equity Q1 2023 · Mar 31, 2023 $222.76M
Stockholders Equity Q1 2023 · Dec 31, 2022 $223.47M
Stockholders Equity Q1 2023 · Mar 31, 2022 $295.82M
Stockholders Equity Q1 2023 · Dec 31, 2021 $319.48M
Current Liabilities Q1 2023 · Mar 31, 2023 $18.16M
Current Liabilities Q1 2023 · Dec 31, 2022 $17.17M
Total Liabilities Q1 2023 · Mar 31, 2023 $21.12M
Total Liabilities Q1 2023 · Dec 31, 2022 $20.36M
Current Assets Q1 2023 · Mar 31, 2023 $205.29M
Current Assets Q1 2023 · Dec 31, 2022 $230.84M
Total Assets Q1 2023 · Mar 31, 2023 $243.88M
Total Assets Q1 2023 · Dec 31, 2022 $278.83M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.73
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.61
Eps Basic Q1 2023 · Mar 31, 2023 −$0.73
Eps Basic Q1 2023 · Mar 31, 2022 −$0.61
Sga Expense Q1 2023 · Mar 31, 2023 $8.09M
Sga Expense Q1 2023 · Mar 31, 2022 $7.41M
Rd Expense Q1 2023 · Mar 31, 2023 $26.56M
Rd Expense Q1 2023 · Mar 31, 2022 $19.65M
Operating Income Q1 2023 · Mar 31, 2023 −$34.65M
Operating Income Q1 2023 · Mar 31, 2022 −$27.06M